Researchers identify possible drug target for prostate cancer
The researchers examined prostate cancer cell lines that model common forms of prostate cancer that are resistant to androgen deprivation therapy. They found that BRD4, but not similar family members BRD2 or BRD3, regulates the expression of key proteins that directly contribute to prostate cancer disease progression.
Researchers have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Bromodomain-containing protein 4 is a protein in humans encoded by the BRD4 gene. Castration-resistant prostate cancer is a highly aggressive form of prostate cancer that often leads to the development of lethal metastases that kills more than 31,000 American men every year.
The standard of care treatment for these patients typically includes disruption of androgen receptor signalling with drugs called `androgen deprivation therapy`.
"While effective for an average of two-three years, this therapy eventually fails to impede cancer progression, due to acquired resistance to the drugs," study authors from Boston University in the US said.
Researchers have long studied a family of three closely-related proteins, called BET bromodomain proteins, composed of BRD2, BRD3 and BRD4, which regulate gene expression.
The researchers examined prostate cancer cell lines that model common forms of prostate cancer that are resistant to androgen deprivation therapy. They found that BRD4, but not similar family members BRD2 or BRD3, regulates the expression of key proteins that directly contribute to prostate cancer disease progression.
"These findings are novel because, until now, it was not clear which of the BET family of proteins regulate transcriptional programmes, or how they influence prostate cancer cell morphology (shape and polarity), motility (the ability to move independently) and invasiveness, each of which is associated with the ability to metastasize.
According to the researchers, this study is significant because current therapeutic options for castration-resistant prostate cancer are limited and focus primarily on suppressing prostate tumour cells that rely on androgen receptor signalling.
"As prostate tumour cells become resistant to therapy, their reliance on androgen receptor signalling is reduced and alternative signalling mechanisms are activated. Out of this complex mixture, the metastatic cells arise," the study authors wrote.
Watch Zee Business live TV below:
The researchers believe it is imperative to identify new targets that regulate the expression of critical transcription factors across diverse prostate cancer cell types in order to block migration and invasion and eventual metastasis.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SRH vs GT IPL 2024 Ticket Booking Online: Where and how to buy SRH vs GT tickets online - Check IPL Match 66 ticket price, other details
Top 7 SWP Mutual Funds: Rs 50 lakh investment, Rs 70K monthly pension for 10 years, and Rs 42.30 lakh balance value; know more details
Gold and Silver rate today (May 13, 2024): Precious metal under pressure; yellow metal near Rs 72,400, white metal above Rs 84,600
SIP Returns: How Rs 3,000, 5,000, and Rs 10,000 SIPs can help you build retirement corpus of Rs 1.06 cr, Rs 1.77 cr, and Rs 3.53 cr
05:23 PM IST